cebo]) and a signiﬁcant decrease in theproinsulin-to-insulin ratio toward morephysiological proportions in the 10- /H9262g exenatide arm ( P/H110210.001), with a similar trend observed in the 5- /H9262g exenatide arm (Fig. 5). Clinical laboratory ﬁndings and safetyExenatide treatment was not associatedwith an increased incidence of cardiovas-cular, hepatic, or renal adverse events. Nochanges in plasma lipids, laboratorysafety parameters, heart rate, blood pres- Figure 5— Week 30 change in fasting proinsulin–to–insulin ratio from baselinein the intent-to-treat population. Dataare mean /H11006SE.DeFronzo and Associates DIABETES CARE,VOLUME 28, NUMBER 5, M AY2005 1097Downloaded from http://diabetesjournals.org/care/article-pdf/28/5/1092/566577/zdc0050500 092.pdf by guest on 17 January 2024